The Effect of Epidermal Growth Factor on Epithelial Healing After Penetrating Keratoplasty in Human Eyes

Kandarakis, Artemios; Page, Catsy; Kaufman, Herbert E.

doi:10.1016/0002-9394(84)90121-1

Cited by 64 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of clinical attempts to demonstrate the beneficial effect of EGF on corneal wound healing have been equivocal (19)(20)(21). This may be due to the fact that EGF is also present in human tears at varying concentrations (our unpublished data).…”

Section: Discussionmentioning

confidence: 98%

Epidermal growth factor-like, corneal wound healing substance in mouse tears.

Tsutsumi¹,

Tsutsumi²,

Oka³

1988

J. Clin. Invest.

View full text Add to dashboard Cite

We have identified the presence of a putative corneal wound healing substance in mouse tears, which has a molecular size and immunological properties similar to those of epidermal growth factor (EGF). The substance was capable of binding to EGF receptors in mouse parenchymal cells and this binding was inhibited by anti-EGF serum. The concentration of the EGF-like substance in the tears of male and female mice was estimated to be 79.3±7.0 (SD) ng/ml and 76.5±8.1 (SD) ng/ml, respectively, by EGF radioimmunoassay. Removal of the submandibular glands, which produce large amounts of EGF, reduced plasma EGF to an undetectable level and also decreased the concentration of the EGF-like substance in tears to 27.3±3.9 (SD) ng/ml in male mice and 25.8±3.7 (SD) ng/ml in female mice. Approximately 50% of sialoadenectomized (submandibular glands removed) male mice with deep corneal wounds developed severe ocular lesions or loss of sight whereas none of normal male mice with similar wounds did. Topical application of EGF to deeply wounded eyes of sialoadenectomized mice eliminated the various complications and restored the healing rate and incidence of recovery to virtually normal levels.

show abstract

Section: Discussionmentioning

confidence: 98%

Epidermal growth factor-like, corneal wound healing substance in mouse tears.

Tsutsumi¹,

Tsutsumi²,

Oka³

1988

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…Topical treatment with SP and IGF-1 induced healing in 2 patients who had disease recurrence within 1 year of follow-up [15,67]. Epidermal growth factor has been used in human clinical trials with conflicting results [68,69]. Topical treatment with NGF represents a promising therapy in the prevention of onset and progression of NK.…”

Section: Treatmentmentioning

confidence: 99%

Neurotrophic Keratitis

et al. 2013

View full text Add to dashboard Cite

Neurotrophic keratitis (NK) is a rare degenerative corneal disease that occurs as a result of partial or total impairment of trigeminal innervations, leading to a reduction (hypoesthesia) in or loss (anaesthesia) of corneal sensitivity. The impairment of sensory innervation causes a reduction in the lacrimation reflex and the vitality, metabolism and mitosis of epithelial cells, with subsequent deficiency in epithelial repair, stromal and intracellular oedema, loss of microvilli, and abnormal development of the basal lamina. Several recent studies have proposed different therapies based on different aetiopathogenetic theories. The aim of the therapy is to treat aetiopathogenesis and, at the same time, promote corneal healing. In this paper, we report the aetiology, diagnosis, management, and medical and surgical treatment of NK, also indicating future treatments based on the most recent studies.

show abstract

“…Several clinical studies of topically applied E G F yield ed promising results of epithelial healing in eyes following corneal trauma, superficial infection, thermal, acid and alkali burns, and corneal surgery [14][15][16][17][18][19]. More recent clinical studies confirmed the efficacy of E G F in the top ical treatment following epikeratoplasty [20,21] and trau matic corneal ulcers [22].…”

Section: Discussionmentioning

confidence: 84%

Epidermal Growth Factor in the Topical Treatment of Herpetic Corneal Ulcers

et al. 1994

View full text Add to dashboard Cite

The tolerability and efficacy of epidermal growth factor (EGF) in the topical treatment of herpetic corneal ulcers in addition to topical acyclovir have been evaluated in a double-blind, placebo-controlled, randomized study in two groups of patients. The time required for complete reepithelialization of the cornea was recorded, and the data obtained were analyzed statistically. In the EGF group, the reepithelialization was significantly faster than in the control group. Tolerability of EGF was always excellent. These results indicate that EGF is safe and effective in reducing the healing time of herpetic corneal ulcers.

show abstract

The Effect of Epidermal Growth Factor on Epithelial Healing After Penetrating Keratoplasty in Human Eyes

Cited by 64 publications

References 6 publications

Epidermal growth factor-like, corneal wound healing substance in mouse tears.

Epidermal growth factor-like, corneal wound healing substance in mouse tears.

Neurotrophic Keratitis

Epidermal Growth Factor in the Topical Treatment of Herpetic Corneal Ulcers

Contact Info

Product

Resources

About